Cash/Burn From SEC Filing For Period: 

Q3 '19

UROV

Urovant Sciences

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.

Cash

$67.8M

Burn Rate

$25.7M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Vibegron

Overactive bladder (OAB)

PDUFA

12/26/2020

Vibegron

OAB in Men with BPH

Phase 3

URO-902

OAB

Ongoing Phase 2a

Vibegron

IBS-Associated Pain

Phase 2

2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon